Roles of Superoxide dismutase(SOD) , Malondialdehyde (MDA), 8-iso-prostaglandinF2α      ( 8-iso-PGF2α)as oxidative stress in development and progression of Brest cancer in Iraqi females patients

Oxidative stress occurs as a result of disturbance in the balance between the production of reactive oxygen species (free radicals) and antioxidant defenses. Markers of oxidative stress were measured the markers of oxidative stress in breast cancer patients after diagnosis of breast cancer and compared these plasma blood levels controls This study was conducted to three markers of oxidative stress ;these are (SOD) enzyme ,malondialdehyde (MDA)and8-iso-prostaglandinF2α plasma of patients with breast cancer and compare with controls .In this study ; the mean MDA (ng/ml) levels for the breast cancer patients and the controls were55.91±3.31 and40.61±3.76 respectively, while the SOD (pg/ml) levels were1530.37±80.4 and1851.4 9±93.65 respectively and the 8-iso-PGF2α (ng/ml ) levels were 40.16±3.31 and 30.16±2.34 difference of the mean were statistically significant (p value <0.05).

Download Full-text

Assessment of oxidative stress in breast cancer patients: a hospital based study

International Journal of Basic & Clinical Pharmacology ◽

10.18203/2319-2003.ijbcp20181644 ◽

2018 ◽

Vol 7 (5) ◽

pp. 966 ◽

Cited By ~ 1

Author(s):

Jagruti Bhattacharjee ◽

Sangita Jogdand ◽

R. K. Shinde ◽

Sourav Goswami

Keyword(s):

Breast Cancer ◽

Oxidative Stress ◽

Superoxide Dismutase ◽

Cancer Patients ◽

Study Participant ◽

Antioxidant Defenses ◽

Blood Levels ◽

P Value ◽

Breast Cancer Patients ◽

The Mean

Background: Oxidative stress occurs as a result of the disturbance in the balance between the production of reactive oxygen species (free radicals) and antioxidant defenses. This is regarded as a possible etilogical factor in production of breast carcinoma, which is the most cmmon cancer among the females both globally as well as in India. Oxidative stress also plays an important role in progression of cancer breast. This study was conducted to compare the levels of superoxide dismutase (SOD) and malondialdehyde (MDA) in breast cancer patients and normal age matched female participants.Methods: This study was conducted in AVBR Hospital, Sawangi (Meghe) among 30 female breast cancer patients admitted in the surgery ward for treatment after being diagnosed with the disease, who attended the hospital from July 2016 to June 2017. Breast cancer patients of stage I and II were included in the study. Patients suffering from any other diseases apart from breast cancer like diabetes, hypertension, thyroid illnesses and other sort of cancers are excluded from the study. For each of the study participant, age and sex matched controls were selected who were mostly the relatives of patients attending the hospital and were devoid of any illnesses. Venous blood sample was collected from all the patients as well as the controls that were used for determination of the levels of SOD (superoxide dismutase) and MDA (malondialdehyde). Written informed consent was taken from all the study participants before drawing the blood samples.Results: Authors have measured the markers of oxidative stress in breast cancer patients after diagnosis of breast cancer and compared theses blood levels with those of the controls. The mean MDA (nmol/ml) levels for the breast cancer patients and the controls were 26.14 and 15.83 respectively, while the SOD (U/gm Hb) levels were 0.12 and 0.16 respectively and the difference of the mean were statistically significant (p value <0.01).Conclusions: There is presence of increased oxidative stress in breast cancer patients as compared to the healthy controls.

Download Full-text

Correlation of AGR2 expression with the incidence of metastasis in luminal breast cancer

Breast Disease ◽

10.3233/bd-219015 ◽

2021 ◽

pp. 1-5

Author(s):

David Samuel Kereh ◽

John Pieter ◽

William Hamdani ◽

Haryasena Haryasena ◽

Daniel Sampepajung ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Mean Value ◽

Rank Test ◽

Luminal Breast Cancer ◽

P Value ◽

Strong Positive Correlation ◽

Breast Cancer Patients ◽

The Mean ◽

Spearman Test

BACKGROUND: AGR2 expression is associated with luminal breast cancer. Overexpression of AGR2 is a predictor of poor prognosis. Several studies have found correlations between AGR2 in disseminated tumor cells (DTCs) in breast cancer patients. OBJECTIVE: This study aims to determine the correlation between anterior Gradient2 (AGR2) expression with the incidence of distant metastases in luminal breast cancer. METHODS: This study was an observational study using a cross-sectional method and was conducted at Wahidin Sudirohusodo Hospital and the network. ELISA methods examine AGR2 expression from blood serum of breast cancer patients. To compare the AGR2 expression in metastatic patients and the non-metastatic patient was tested with Mann Whitney test. The correlation of AGR2 expression and metastasis was tested with the Rank Spearman test. RESULTS: The mean value of AGR2 antibody expression on ELISA in this study was 2.90 ± 1.82 ng/dl, and its cut-off point was 2.1 ng/dl. Based on this cut-off point value, 14 subjects (66.7%) had overexpression of AGR2 serum ELISA, and 7 subjects (33.3%) had not. The mean value AGR2 was significantly higher in metastatic than not metastatic, 3.77 versus 1.76 (p < 0.01). The Spearman rank test obtained a p-value for the 2 tail test of 0.003 (p < 0.05), which showed a significant correlation of both, while the correlation coefficient of 0.612 showed a strong positive correlation of AGR2 overexpression and metastasis. CONCLUSIONS: AGR2 expression is correlated with metastasis in Luminal breast cancer.

Download Full-text

Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer

Cancers ◽

10.3390/cancers13010147 ◽

2021 ◽

Vol 13 (1) ◽

pp. 147

Author(s):

Leticia Díaz-Beltrán ◽

Carmen González-Olmedo ◽

Natalia Luque-Caro ◽

Caridad Díaz ◽

Ariadna Martín-Blázquez ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Biomarker Discovery ◽

Molecular Subtypes ◽

Breast Cancer Subtype ◽

P Value ◽

Plasma Samples ◽

Breast Cancer Patients ◽

Clinical Value ◽

Molecular Phenotypes

Purpose: The aim of this study is to identify differential metabolomic signatures in plasma samples of distinct subtypes of breast cancer patients that could be used in clinical practice as diagnostic biomarkers for these molecular phenotypes and to provide a more individualized and accurate therapeutic procedure. Methods: Untargeted LC-HRMS metabolomics approach in positive and negative electrospray ionization mode was used to analyze plasma samples from LA, LB, HER2+ and TN breast cancer patients and healthy controls in order to determine specific metabolomic profiles through univariate and multivariate statistical data analysis. Results: We tentatively identified altered metabolites displaying concentration variations among the four breast cancer molecular subtypes. We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected p-value < 0.05 and a fold-change cutoff value > 1.3. The model clinical value was evaluated with the AUROC, providing diagnostic capacities above 0.85. Conclusion: Our study identifies metabolic profiling differences in molecular phenotypes of breast cancer. This may represent a key step towards therapy improvement in personalized medicine and prioritization of tailored therapeutic intervention strategies.

Download Full-text

Lesion-Based Bone Metastasis Detection in Chest Bone Scintigraphy Images of Prostate Cancer Patients Using Pre-Train, Negative Mining, and Deep Learning

Diagnostics ◽

10.3390/diagnostics11030518 ◽

2021 ◽

Vol 11 (3) ◽

pp. 518

Author(s):

Da-Chuan Cheng ◽

Te-Chun Hsieh ◽

Kuo-Yang Yen ◽

Chia-Hung Kao

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Deep Learning ◽

Bone Metastasis ◽

Cancer Patients ◽

Bone Scintigraphy ◽

Breast Cancer Patients ◽

Location Detection ◽

The Mean ◽

Mean Sensitivity

This study aimed to explore efficient ways to diagnose bone metastasis early using bone scintigraphy images through negative mining, pre-training, the convolutional neural network, and deep learning. We studied 205 prostate cancer patients and 371 breast cancer patients and used bone scintigraphy data from breast cancer patients to pre-train a YOLO v4 with a false-positive reduction strategy. With the pre-trained model, transferred learning was applied to prostate cancer patients to build a model to detect and identify metastasis locations using bone scintigraphy. Ten-fold cross validation was conducted. The mean sensitivity and precision rates for bone metastasis location detection and classification (lesion-based) in the chests of prostate patients were 0.72 ± 0.04 and 0.90 ± 0.04, respectively. The mean sensitivity and specificity rates for bone metastasis classification (patient-based) in the chests of prostate patients were 0.94 ± 0.09 and 0.92 ± 0.09, respectively. The developed system has the potential to provide pre-diagnostic reports to aid in physicians’ final decisions.

Download Full-text

Aesthetic outcome and patient’s quality of life in breast cancer patients undergoing mastectomy with or without immediate reconstruction.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e12587 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e12587-e12587

Author(s):

Sidra Afzal ◽

Asad Parvaiz ◽

Nida Javed

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Well Being ◽

Mean Difference ◽

Breast Cancer Patients ◽

Immediate Reconstruction ◽

Patient’S Satisfaction ◽

Group A ◽

The Mean ◽

Group B

e12587 Background: : Although post mastectomy Immediate breast reconstruction has shown to improve physical and psychosocial well-being of breast cancer patients, this is not a usual procedure in Pakistan due to limited resources and lack of awareness. The aim of our study is to evaluate patient’s satisfaction/ aesthetic outcomes between the patients undergoing mastectomy alone (Group A) and the ones undergoing mastectomy followed by immediate reconstruction (Group B). Methods: This is a prospective study conducted at Shaukat Khanum Hospital Pakistan comparing aesthetic outcome, patient’s satisfaction and Quality of life between two groups using Breast Q module. All patients undergoing mastectomy with and without reconstruction between April 2017 to July 2019 are included. Sample size of 84 was calculated (42 in each group). Results: The mean Q score of satisfaction with the breast in group B is 82.64 and in group A is 35.82 (P = 0.001). The mean Q score of Psychosocial well-being in group B is 89 vs 44.95 in group A (P = 0.001). The mean Q score of Physical well-being in group B is 98.23 vs 90.41 in group A (P = 0.002). The mean Q score of sexual well-being in group B is 81.93 vs 43 in Group A (P = 0.001). [Mean difference in score of 5-10 - little change, 10-20 - moderate change, > 20 - significant change].The mean difference between two groups in satisfaction with breast , psychosocial well-being and sexual well-being is more than 20 with a statistically significant p-value, while in physical well-being the mean difference is 7.8 which falls in little change group. Conclusions: Our study shows that reconstruction helps breast cancer patients in providing comprehensive care in a manner that they achieve a higher satisfaction with their appearance, psychological and sexual well-being without compromising oncological safety and this should be practiced more in our country. Also patients education about these procedures should be raised to help them fighting against this disease

Download Full-text

Hubungan Dukungan Keluarga Terhadap Kualitas Hidup Pasien Kanker Payudara di Rumah Sakit Islam Siti Khodijah Palembang Tahun 2018

Jurnal Ilmiah Universitas Batanghari Jambi ◽

10.33087/jiubj.v19i3.698 ◽

2019 ◽

Vol 19 (3) ◽

pp. 529

Author(s):

Yofa Anggriani Utama

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Developing Countries ◽

Family Support ◽

Cancer Patients ◽

Sampling Technique ◽

P Value ◽

Breast Cancer Patients ◽

The World

Cancer is one of the causes of death in both developed and developing countries, cancer is increasing in developing countries due to increasing lifestyle, breast cancer is a cancer that causes death in women in the world, breast cancer is the highest contributor to mortality in women in the world, 43.3 per 100,000. The purpose of this study was to determine the relationship of family support to the quality of life of breast cancer patients. The research design used was observational analytic with cross sectional approach. The sampling technique used purposive sampling technique, the study sample amounted to 63 breast cancer patients. The results show that there is a relationship between family support and the quality of life of breast cancer patients with a p value of 0.032. shows there is a relationship between family support for the quality of life of patients with breast cancer. Suggestions that nurses can improve the quality of nursing services, and provide motivation to patients and families of breast cancer in carrying out breast cancer treatment.

Download Full-text

PENGARUH LATIHAN JALAN KAKI TERHADAP KUALITAS TIDUR PADA PASIEN KANKER PAYUDARA YANG MENJALANI KEMOTERAPI DI RSUP DR. M DJAMIL PADANG

JURNAL KESEHATAN MERCUSUAR ◽

10.36984/jkm.v3i1.80 ◽

2020 ◽

Vol 3 (1) ◽

pp. Page16-27

Author(s):

Weny Amelia ◽

Mira Andika ◽

Diana Yulanda

Keyword(s):

Breast Cancer ◽

Sleep Quality ◽

Cancer Patients ◽

Quality Index ◽

Quality Score ◽

P Value ◽

Breast Cancer Patients ◽

Quality Of Sleep ◽

Walking Exercise

Abstrak Kemoterapi merupakan salah satu modalitas pengobatan kanker untuk mengatasi stadium lokal maupun metastase. Masalah yang sering muncul pada pasien kanker payudara yang menjalani kemoterapi adalah gangguan tidur sehingga berpengaruh terhadap kualitas tidur pasien. Penurunan kualitas tidur yang dialami oleh pasien kanker payudara yang menjalani kemoterapi dapat diatasi dengan latihan jalan kaki. Latihan jalan kaki merupakan kegiatan atau aktivitas yang dilakukan dengan menggunakan kedua kaki yang diikuti dengan ayunan tangan atau bagian anggota tubuh secara sinergis. Tujuan penelitian ini adalah untuk melihat pengaruh latihan jalan kaki terhadap kualitas tidur padapasien kanker payudara yang menjalani kemoterapi. . Penelitian ini dilakukan di RSUP Dr. M.Djamil Padang. Waktu penelitian ini dimulai pada tanggal 4-9 September 2019. Penelitian ini menggunakan pre eksperimet design dengan rancangan one group pretest-posttest design. Pengumpulan data dilakukan dengan menggunakan kuesioner PSQI (Pittsburgh Quality Index) untuk mengetahui kualitas tidur pasien berupa latihan jalan kaki selama 30 menit dilakukan 3 kali dalam 3 hari. . Hasil penelitian dengan uji statistik uji paired sampel t-test didapatkan bahwa rata-rata skor kualitas tidur sebelum intervensi 12.16 dan rata-rata skor kualitas tidur setelah intervensi 7.16. Penelitian ini menemukan perbedaan bermakna peningkatan kualitas tidur sebelum dan setelah intervensi p value = 0,000 ( p< 0.05) sehingga dapat disimpulkan bahwa terdapat pengaruh latihan jalan kaki terhadap kualitas tidur pasien kanker payudara yang menjalani kemoterapi. . Disarankan kepada perawat untuk memberikan edukasi latihan jalan kaki kepada pasien kanker payudara yang menjalani kemoterapi untuk meningkatkan kualitas tidur pasien, sehingga dapat meningkatkan kondisi kesehatan pasien secara umum yang nantinya dapat memperbaiki dan meningkatkan kualitas hidup pasien kanker payudara. Kata Kunci : Latihan Jalan kaki, Kualitas Tidur, Kanker Payudara, Kemoterapi Abstract Chemotherapy is one of the modalities of cancer treatment to overcome the local stage and metastasis. The problem that often arises in breast cancer patients undergoing chemotherapy is sleep disorders that affect the patient's sleep quality. Decreased sleep quality experienced by breast cancer patients undergoing chemotherapy can be overcome by walking exercises. Walking exercises are activities or activities carried out using both legs followed by swinging hands or parts of the body synergistically. The purpose of this study was to look at the effect of walking training on sleep quality in breast cancer patients undergoing chemotherapy. . This research was conducted at the Dr. M.Djamil Padang. When this study began on September 4-9, 2019. This study used a pre-experimental design with one group pretest-posttest design. Data collection was carried out using a PSQI (Pittsburgh Quality Index) questionnaire to determine the quality of sleep of patients in the form of 30 minutes of walking exercises performed 3 times in 3 days. . The results of the study with the statistical test paired sample t-test found that the average sleep quality score before the intervention was 12.16 and the average sleep quality score after the intervention was 7.16. This study found a significant difference in the improvement of sleep quality before and after the intervention p value = 0,000 (p <0.05) so that it can be concluded that there is an effect of walking exercise on the sleep quality of breast cancer patients undergoing chemotherapy. . It is recommended to nurses to provide education on walking exercises to breast cancer patients undergoing chemotherapy to improve the quality of sleep of patients, so as to improve the general health condition of patients who can later improve and improve the quality of life for breast cancer patients. Keywords: Breast Cancer, Chemotherapy, Sleep Quality, Walking Exercise

Download Full-text

COVID-related anxiety is prevalent and accurately reflects serious COVID risks in breast cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.12053 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. 12053-12053

Author(s):

Marisa C. Weiss ◽

Stephanie Kjelstrom ◽

Meghan Buckley ◽

Adam Leitenberger ◽

Melissa Jenkins ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Cancer Diagnosis ◽

Breast Cancer Diagnosis ◽

P Value ◽

Breast Cancer Patients ◽

Chi Square ◽

Liver And Kidney ◽

Chi Square Test ◽

A Current

12053 Background: A current cancer diagnosis is a risk factor for serious COVID-19 complications (CDC). In addition, the pandemic has caused major disruptions in medical care and support networks, resulting in treatment delays, limited access to doctors, worsening health disparities, social isolation; and driving higher utilization of telemedicine and online resources. Breastcancer.org has experienced a sustained surge of new and repeat users seeking urgent information and support. To better understand these unmet needs, we conducted a survey of the Breastcancer.org Community. Methods: Members of the Breastcancer.org Community were invited to complete a survey on the effects of the COVID-19 pandemic on their breast cancer care, including questions on demographics, comorbidities (including lung, heart, liver and kidney disease, asthma, diabetes, obesity, and other chronic health conditions); care delays, anxiety due to COVID-related care delays, use of telemedicine, and satisfaction with care during COVID. The survey was conducted between 4/27/2020-6/1/2020 using Survey Monkey. Results were tabulated and compared by chi square test. A p-value of 0.05 is considered significant. Data were analyzed using Stata 16.0 (Stata Corp., Inc, College Station, TX). Results: Our analysis included 568 breast cancer patients of whom 44% had ≥1 other comorbidities associated with serious COVID-19 complications (per CDC) and 37% had moderate to extreme anxiety about contracting COVID. This anxiety increased with the number of comorbidities (p=0.021), age (p=0.040), and with a current breast cancer diagnosis (p=0.011) (see table). Anxiety was significantly higher in those currently diagnosed, ≥65, or with ≥3 other comorbidities, compared to those diagnosed in the past, age <44, or without other comorbidities. Conclusions: Our survey reveals that COVID-related anxiety is prevalent at any age regardless of overall health status, but it increased with the number of other comorbidities, older age, and a current breast cancer diagnosis. Thus, reported anxiety is proportional to the risk of developing serious complications from COVID. Current breast cancer patients of all ages—especially with other comorbidities—require emotional support, safe access to their providers, and prioritization for vaccination.[Table: see text]

Download Full-text

Survival Outcomes In Human Epidermal Growth Factor Receptor 2 (HER 2) Positive Breast Cancer Patients At Kenyatta National Hospital

10.21203/rs.3.rs-809737/v1 ◽

2021 ◽

Author(s):

Gloria Tuwei ◽

Amsalu Degu

Keyword(s):

Breast Cancer ◽

Survival Rate ◽

Cancer Patients ◽

Survival Outcomes ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Predictors Of Mortality ◽

Her2 Positive Breast Cancer ◽

The Mean ◽

Positive Breast Cancer

Abstract Background: For several years, HER2-positive breast cancer was associated with poor outcomes and higher mortality rates than other breast cancer subtypes. Nevertheless, the advent of Trastuzumab has significantly changed the treatment paradigm of HER2-positive breast cancer. However, it is not an affordable treatment option in sub-Saharan African countries. Besides, there was a lack of comprehensive data about the survival outcomes of HER2-positive breast cancer patients in our setting. Hence, the present study aimed to determine the survival outcomes among HER2-positive breast cancer patients at the Oncology Department of Kenyatta National Hospital.Methods: A hospital-based retrospective cohort design was used to evaluate the survival outcomes, and associated factors among patients with HER2-positive breast cancer admitted between 2015 and 2019 at Kenyatta National Hospital. A total of 50 eligible HER2-positive breast cancer patients were included in the study. In the pre-designed data abstraction tool, the data were collected by reviewing the medical records of the patients. The data were entered and analyzed using the Statistical Package for the Social Sciences version 27 software. The mean survival time was estimated using Kaplan Meier survival analysis. Cox regression analysis was employed to estimate the predictors of mortality among HER2-positive breast cancer patients.Results: The study showed that the overall survival rate was 30%, with a significant decrease in the percentage survival rate across the five years. More than half of the study participants (26, 52%) showed cancer progression during the last follow-up period. The present study showed that the mean cancer-specific survival rate among the study patients was 26.74±18.395 months. The study showed that the mean survival time of patients aged below 60 years (32.513 months), without co-morbidities (34.40 months), and the early stage of the disease (50.639 months) was higher than their counterparts. Multivariate cox-regression analysis revealed that advanced stage (AHR=13.1, 95% CI=2.6-66.6, P=0.002 and distant metastasis (AHR=15.0, 95% CI=3.6-62.8, P≤0.001) were the significant predictors of mortality among HER2 positive breast cancer patients.Conclusions: The overall survival rate of HER 2 positive breast cancer was 30%. Advanced stage and distant metastasis were the significant predictors of mortality among HER2-positive breast cancer patients.

Download Full-text

Assessment of cardiotoxicity in hormone positive postmenopausal breast cancer patients receiving aromatase inhibitors

Journal of Solid Tumors ◽

10.5430/jst.v9n1p11 ◽

2019 ◽

Vol 9 (1) ◽

pp. 11

Author(s):

Reham M. Faheim ◽

Eman A. El-Shaarawy ◽

Dina A. Salem ◽

Rehab G. Shaaban

Keyword(s):

Breast Cancer ◽

Blood Pressure ◽

Lipid Profile ◽

Cancer Patients ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Postmenopausal Breast Cancer ◽

P Value ◽

Breast Cancer Patients ◽

Hormone Receptor Positive

Background: Aromatase inhibitors (AIs) represent an effective endocrine treatment for hormone receptor-positive postmenopausal breast cancer patients with early stage or metastatic disease.Objective: Assessment of Cardiotoxicity in Hormone positive Postmenopausal Breast Cancer Patients receiving AIs (upfront orswitch therapy).Methods: This cross sectional study included 123 postmenopausal breast cancer patients presented to the Clinical Oncology Department, Ain Shams University (Cairo, Egypt) in the interval from August 2016 to June 2017 with hormone receptor positive receiving Aromatase Inhibitors, To assess cardiotoxicity in these patients, they were subjected to blood pressure and lipid profile measurement, electrocardiography (ECG), and electrocardiography (ECHO) and classified into patients had Nolvadex then A.I (arm 1) and others had upfront A.I (arm 2).Results: The age of patients ranged from 41 years to 85 years with mean age of 61 years. Seventy one patients (57.7%) showed cardiotoxicity as assessed by ECHO. They showed significant correlation with rising age above 62 years, IHD, history of HTN and DM (p value: .001, .001, .017 and 0.035 respectively). However, correlation between cardiotoxity and blood pressure changes, lipid profile changes and ECG findings and ECHO changes in switch therapy and upfront A.I were not statistically significant (p value = .275, .116, .081 and .761 respectively).Conclusion: Assessment of cardiotoxicity in hormone positive postmenopausal breast cancer patients receiving Aromatase Inhibitors showed evidence of cardiotoxicity in half the patients (57.7%) as detected by ECHO only. They showed statistically non significant correlations either recievied switch therapy or upfront A.I.

Download Full-text